HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 2, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the second quarter ended June 30, 2017 . “With positive progress in our lead Alzheimer’s and diabetes programs, vTv is
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 13, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), will be presented at the 2017
Lower doses of TTP273 may demonstrate a more pronounced reduction in HbA1c and other key endpoints HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 11, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced
-- Azeliragon is the only RAGE receptor antagonist in clinical development for Alzheimer’s Disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 1, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced the completion of enrollment for vTv’s Phase 3 placebo-controlled trial, STEADFAST
HIGH POINT, N.C. --(BUSINESS WIRE)--May 3, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today provided
HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 10, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today
Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer’s Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273 and TTP399 HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage
Oral small molecule GLP-1 receptor agonist met primary endpoint Company’s second successful Phase 2 diabetes trial in 2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 14, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced positive data from its Phase 2 study evaluating TTP273, an oral